Could a double-drug punch shrink head and neck tumors before radiation?
Disease control
Recruiting now
This study tests whether adding an immunotherapy drug (pucotenlimab) to a targeted therapy (MRG003) before standard chemoradiation can shrink tumors more effectively than MRG003 alone in people with advanced head and neck cancer. About 106 adults aged 18–75 will take part. The go…
Phase: PHASE2 • Sponsor: Groupe Oncologie Radiotherapie Tete et Cou • Aim: Disease control
Last updated May 15, 2026 11:55 UTC